3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
5
Myeloid
4
Lymphoid
4
Gynecologic
2
Gastrointestinal
2
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
Genitourinary
1
CNS
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
33
Injections
28
Pemetrexed
15
Interviews as Topic
15
Carboplatin
14
tislelizumab
13
Cisplatin
13
Specimen Handling
12
Bevacizumab
11
atezolizumab
10
Nivolumab
10
Practice Guidelines as Topic
9
Educational Status
9
Cyclophosphamide
9
Standard of Care
8
Oxaliplatin
8
Fluorouracil
8
fludarabine
7
Methods
7
Early Intervention, Educational
7
Docetaxel
7
Cetuximab
7
Capecitabine
7
toripalimab
6
sotorasib
6
Paclitaxel
6
Leucovorin
6
olaparib
5
Platinum
5
Ipilimumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Blood Component Removal
×
Other solid neoplasm
×
90 days
×
Clear all
NCT04981119
2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
200 enrolled